Objective-To investigate whether an appropriate combination of maternal serum inhibin A, free -human chorionic gonadotropin (free -hCG), unconjugated estriol (uE 3 ), and alpha-fetoprotein (AFP) may be an eVective means of screening for pre-eclampsia in the second trimester of pregnancy. Setting-Women who attended an antenatal clinic in Oxford, from whom serum samples were stored, 19 of whom subsequently developed pre-eclampsia. Methods-Serum inhibin A, free -hCG, uE 3 , and AFP were measured in 32 serum samples collected from the 19 women who developed pre-eclampsia and, for each sample, in three control samples collected from women with unaVected pregnancies matched for gestational age and maternal age. Results-In pregnancies that developed pre-eclampsia the median inhibin A value was raised (1.7 multiples of the median (MoM) for unaVected pregnancies (95% confidence interval (95% CI) 1.1 to 2.7 MoM), the median free -hCG was raised (2.1, 1.4 to 3. 3 MoM) and the median uE 3 was lowered (0.8, 0.6 to 0.98 MoM) after 19 completed weeks of gestation and at least 2 weeks before the onset of proteinuria. Values of AFP were similar in aVected and unaVected pregnancies. Combining the values of inhibin A, free -hCG, and uE 3 to form a screening test would detect an estimated 55% of aVected pregnancies with a false positive rate of 5%. Conclusions-Inhibin A, free -hCG, and uE 3 in combination may be a useful screening test during the second trimester for pre-eclampsia. (J Med Screen 2001;8:65-68) 
Pre-eclampsia and eclampsia are important causes of fetal and maternal morbidity and mortality. A United Kingdom survey in 1992 showed that eclampsia aVected about 1 in 2000 pregnancies in the United Kingdom; one in 50 aVected women died of the condition, as did one in 14 of their babies. 1 In the survey there were 383 cases of eclampsia, among which seven mothers and 30 babies died. 1 Preeclampsia, the precursor of the condition, can have an explosive course, so screening for preeclampsia may be desirable. 2 Several studies have measured diVerent markers (all used in antenatal screening for Down's syndrome 3 ) in stored serum samples collected before the onset of pre-eclampsia. In general these studies have shown that human chorionic gonadotropin (hCG) and inhibin A are increased in pregnancies that later develop pre-eclampsia. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Inconsistent results have been published on alpha-fetoprotein (AFP) and the subsequent development of pre-eclampsia 6 7 9 17-19 and one study suggested that lower unconjugated estriol (uE 3 ) was associated with the subsequent development of pre-eclampsia. 19 One study considered the predictive power of combining two serum markers (inhibin A and free -hCG), 8 but none have considered the predictive power of combining more than two serum markers (as is done in antenatal screening for Down's syndrome). We report here the results of a study to investigate all four of these markers to determine whether a combination would be an eVective screening test for pre-eclampsia in the second trimester of pregnancy.
Methods
We used serum samples collected during the 1970s from the John RadcliVe Maternity Hospital as part of a study of factors that might predict the outcome of pregnancy, and that were used principally in the development of antenatal screening for neural tube defects and Down's syndrome. As part of this study, during a short period around 1974, a selection of cases of pre-eclampsia was identified by Dr Christopher Redman, and linked to the antenatal serum samples we had stored. At the time, the main purpose was to look at values of AFP relative to pre-eclampsia. The cases of preeclampsia that were identified, and matched controls, were retrieved to investigate this further, with particular reference to the value of maternal serum inhibin A, hCG, uE 3 , and AFP, in the prediction of pre-eclampsia. The cases of pre-eclampsia were identified at the time on the basis of fulfilling all the following criteria: (a) a rise in both systolic and diastolic blood pressure during pregnancy of at least 30 and 20 mm of Hg respectively, compared with the level found at the first antenatal booking visit; (b) proteinuria greater than 100 mg/l in a mid-stream urine sample; and (c) possible renal impairment as judged by the increase of plasma uric acid to concentrations of 357 µmol/l or more. Although these criteria may not form a standard definition of preeclampsia, they are sound and have been used in clinical practice.
Nineteen women with pre-eclampsia as already defined had had blood samples taken after 8 weeks' gestation, stored at -40°C. Nine women had one sample, seven had two samples, and three had three samples. For each sample we identified three unaVected pregnancies, selected at random from the patients attending the hospital who had provided a blood sample at the same gestational age in the same calendar quarter and were the same age. Neither aVected nor unaVected pregnancies were associated with Down's syndrome or neural tube defects. None of the samples had been thawed previously. Serum AFP and free -hCG were measured with the Wallac-Delfia kit, uE 3 with the Ortho Clinical Diagnostics kit, and inhibin A with the assay kit produced by Serotec. For each serum marker, the median value in the unaVected pregnancies at each week of gestation was plotted on a logarithmic scale against gestational age, and a regression line was fitted. From this regression line the normal median value for each marker at each week of gestation was estimated and for each sample the marker value was expressed as a multiple of this normal median (MoM) value.
The median marker levels in aVected pregnancies were estimated from the antilogarithm of the mean of the log (MoM) values. The confidence intervals (95% CIs) for these medians were adjusted with Hubert's formulae to take account of the fact that some of the women provided several samples (using the computer package STATA). 20 The means (SDs) of the log (MoM) values in aVected and unaVected pregnancies were calculated for the serum markers in a restricted set of samples taken after 19 weeks of gestation and at least 2 weeks before the onset of proteinuria. The serum markers in this set had approximately log gaussian distributions, and the detection and false positive rates were calculated with a multivariate gaussian model based on the estimated means, SDs, and correlation coeYcients, as is standard practice in antenatal screening for Down's syndrome. 21 Results Table 1 shows the specified marker levels in the pregnancies with pre-eclampsia, together with a restricted analysis relating to samples taken at 20 weeks or later, according to the onset of proteinuria. Inhibin A and free -hCG values were significantly increased in the pregnancies with pre-eclampsia and uE 3 values were lowered. The diVerences in marker values between aVected and unaVected pregnancies were greatest after 19 weeks of gestation. Table 2 shows the marker values in samples taken after 19 weeks of gestation and before the onset of proteinuria according to the interval between sample collection and the onset of proteinuria. In this table there is just one sample for each woman. Inhibin A and free -hCG values increased with decreasing time before the onset of proteinuria whereas uE 3 values decreased. Between 2 and 4 weeks before the onset of proteinuria the median inhibin A value was 2.9 MoM (95% CI 1.9 to 4.6 MoM) and the median free -hCG value was 3.1 MoM (95% CI 1.2 to 8.1). These two markers were increased as early as 7 weeks before the onset of proteinuria. The median uE 3 value was significantly reduced in pregnancies with preeclampsia 2 to 4 weeks before the onset of proteinuria with a value of 0.5 MoM (95% CI 0.4 to 0.6). The AFP values were not significantly altered in the aVected pregnancies, although there was a trend towards increasing values as the time interval decreased. Figure 1 shows probability plots of the distributions of inhibin A, free -hCG, and uE 3 in aVected and unaVected pregnancies with gestations of 20 weeks or greater, the time our results suggest that screening may be eVective. The plots are reasonably straight lines, indicating that the distributions are approximately log gaussian. This means that the screening performance of a test based on these markers can be estimated from the means, SDs, and correlations between the markers. Table 3 shows the means, SDs, and correlation coeYcients of the markers for the aVected and unaVected pregnancies. The SDs for these markers were estimated by fitting regression lines to the data in the figures excluding the points lying outside the 10th-90th percentile range. One unaVected pregnancy with an outlying uE 3 value (greater than 3.5 SDs from the mean value) was excluded in the calculation of the correlation coeYcients. The high correlation between inhibin A and free -hCG in aVected pregnancies may have arisen due to chance and would need to be reassessed in a larger data set. Table 4 summarises the estimated performance of screening tests based on diVerent combinations of inhibin A, free -hCG, and uE 3 measured from 20 weeks of gestation based on the distribution parameters shown in table 3.
The data are restricted to samples collected at least 2 weeks before the detection of proteinuria. The detection rates for pre-eclampsia are shown for a 5% false positive rate, and false positive rates for a 60% detection rate. For example, for a 5% false positive rate, the estimated detection rate is 55% using all three markers, or 47% using only inhibin A and free -hCG.
Discussion
Although there were few samples, our results show that inhibin A, free -hCG, and uE 3 are associated with the subsequent development of pre-eclampsia from about 20 weeks of pregnancy. Each marker provided independent predictive information because, in general, they were not highly correlated in unaVected pregnancies.
Several studies 7 8 11-16 concluded that inhibin A may be predictive of pre-eclampsia before 20 weeks, and two of these showed that the value for inhibin A was higher closer to the onset of pre-eclampsia, 11 16 as we found in our data. In the five studies 7 12 14 15 17 in which the median MoM of inhibin A for aVected pregnancies was given, the values ranged from 1.4 to 2.0 MoM, consistent with our result of 1.7 MoM. Two studies did not find that inhibin A was predictive, but these studies lacked the statistical power to detect a useful eVect. 17 22 Seven studies, 4-10 like ours, found that free -hCG was predictive of pre-eclampsia in the second trimester, but two other studies 17 19 did not show this. In our data, free -hCG values increased closer to the onset of pre-eclampsia; Figure 1 Probability plot of inhibin A, free -hCG, and uE 3 values in maternal serum in pregnancies with pre-eclampsia and unaVected pregnancies collected at 20 weeks of gestation or later before the onset of proteinuria. MoM=multiples of the normal median for unaVected pregnancies of the same gestational age. at 14 to 8 weeks before the onset of pre-eclampsia no eVect was found, and this may explain why no eVect was found early in the second trimester in the two negative studies. Three studies suggested that AFP was predictive of severe pre-eclampsia, 9 17 18 but the eVect is small; in one of the studies the detection rate was only 3% for a false positive rate of 2%, 9 and as we found, Stamilio et al 19 reported that AFP was not a useful marker for pre-eclampsia. There is little evidence to support the use of AFP as a screening test for pre-eclampsia.
Stamilo et al did find that uE 3 may be of value for this; women with values less than 0.9 MoM had an increased risk of pre-eclampsia compared with women with values greater than 0.9 MoM (relative risk 1.7; 95% CI (0.9 to 3.4)). Our results confirm this suggestion.
Despite the small size of our study, it had sufficient power to yield significant diVerences for inhibin A, free -hCG, and uE 3 . We have calculated detection rates and false positive rates to give a preliminary estimate of the eYcacy of screening. Another study 8 calculated detection rates and false positive rates for inhibin A and free -hCG in combination and estimated a detection rate of 49% for a false positive rate of 5%; close to the corresponding detection rate of 47% from our data. With uE 3 as well, the detection rate is significantly higher (55%, table 4 ). If the prevalence of pre-eclampsia were 5%, then the odds of being aVected given a positive result would be about 1:2.
The markers used in this study are also used in screening for Down's syndrome at around 15 to 16 weeks of pregnancy. Further studies are required to determine if the same samples collected for screening for Down's syndrome can be used eVectively in screening for pre-eclampsia. Existing studies 4-19 22 leave the issue open. If these early samples are not adequate for screening for pre-eclampsia, the tests would have to be repeated later in pregnancy, possibly involving a second antenatal visit. In some centres women are advised to attend at this time for a detailed ultrasound examination for the detection of major structural abnormalities. At such centres the same visit could be used to obtain a blood sample to screen for pre-eclampsia.
The only definitive remedy in pre-eclampsia is to deliver the baby and the placenta. There is a consensus that drugs to lower blood pressure are indicated in women with high blood pressure in pregnancy, 23 so they may help to control the blood pressure for maternal reasons, recognising that this does not necessarily mean that such drugs will prevent preeclampsia. There is also evidence that the use of antiplatelet agents such as aspirin can help prevent pre-eclampsia. 24 For example, there was a 15% reduction in the risk of preeclampsia associated with the use of antiplatelet agents (95% CI 8%-22% reduction) based on the results of 32 randomised trials. 24 There is also evidence that supplementation with vitamins C and E may be beneficial in the prevention of pre-eclampsia. 25 It would be desir-able to link the introduction of screening for pre-eclampsia to controlled trials designed to show whether preventive treatment in women found to be at high risk of pre-eclampsia is eVective in reducing the incidence or severity of the disease.
